stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Free cash flow
Travere Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$20.4M, compared with −$273.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $85.3M. Over the past ten years it has ranged from −$322.3M (fiscal 2023) to $140.0M (fiscal 2015); the current reading is higher than 73% of that period. Travere Therapeutics, Inc. ranks 30th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$20.4M | — |
| FY2024 | −$273.7M | — |
| FY2023 | −$322.3M | — |
| FY2022 | −$214.8M | — |
| FY2021 | −$38.9M | — |
| FY2020 | −$67.3M | — |
| FY2019 | −$73.8M | — |
| FY2018 | −$44.7M | — |
| FY2017 | −$6.6M | — |
| FY2016 | −$15.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $69.5M | 87.71% |
| Jun 2026 | $37.0M | — |
| Mar 2026 | −$62.5M | — |
| Dec 2025 | $41.4M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. | $85.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$121.8M |
| MANE Veradermics Incorporated compare | −$123.0M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$202.3M |
| ERAS Erasca, Inc. compare | −$252.1M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| CRSP CRISPR Therapeutics AG compare | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement